A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Trial Profile

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AURORA
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 According to an Aurinia Pharmaceuticals media release, the company is on track to complete the enrollment in eighteen months.
    • 17 May 2017 According to an Aurinia Pharmaceuticals Inc. media release, the first patient has been dosed in this trial.
    • 15 May 2017 Status changed from not yet recruiting to recruiting, according to an Aurinia Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top